Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates

About this update from Jaguar Health, Inc.

[{"type":"text","content":"Click here to register","length":22,"tagName":"p"},{"type":"text","content":"Company plans to file its Earnings Report on May 15, 2025 on Form 10-Q for the quarter ended March 31, 2025","length":107,"tagName":"p"},{"type":"text","content":"SAN FRANCISCO, CA / ACCESS Newswire / May 14, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast tomorrow, Thursday, May 15, 2025, at 4:15 p.m. Eastern to review first-quarter 2025 financials and provide corporate updates.","length":278,"tagName":"p"},{"type":"text","content":"Participation Instructions for Investor Webcast","length":47,"tagName":"p","attribs":{}},{"type":"text","content":"When: Thursday, May 15, 2025 at 4:15 PM Eastern Standard Time","length":61,"tagName":"p","attribs":{}},{"type":"text","content":"Participant Registration & Access Link: Click Here","length":54,"tagName":"p","attribs":{}},{"type":"text","content":"About the Jaguar Health Family of Companies","length":43,"tagName":"p"},{"type":"text","content":"Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health ind...

More updates from Jaguar Health, Inc.